Evidence map›Paper›PMID 36615273›Full record

ArticleMolecules (Basel, Switzerland)2022

Studies on 1,4-Quinone Derivatives Exhibiting Anti-Leukemic Activity along with Anti-Colorectal and Anti-Breast Cancer Effects.

Halilibrahim Ciftci, Belgin Sever, Nusret Kaya, Nilüfer Bayrak, Mahmut Yıldız, Hatice Yıldırım, Hiroshi Tateishi, Masami Otsuka, Mikako Fujita, Amaç Fatih TuYuN

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 2 countries.

Halilibrahim CiftciDepartment of Drug Discovery, Science Farm Ltd., Kumamoto 862-0976, Japan.ORCID 0000-0002-9796-7669
Belgin SeverMedicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto 862-0973, Japan.ORCID 0000-0003-4847-9711
Nusret KayaMedicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto 862-0973, Japan.ORCID 0000-0003-1727-3155
Nilüfer BayrakDepartment of Chemistry, Faculty of Science, Istanbul University, Fatih, Istanbul 34126, Turkey.
Mahmut YıldızChemistry Department, Gebze Technical University, Gebze, Kocaeli 41400, Turkey.ORCID 0000-0001-6317-5738
Hatice YıldırımDepartment of Chemistry, Faculty of Engineering, Istanbul University-Cerrahpasa, Avcılar, Istanbul 34320, Turkey.ORCID 0000-0003-3988-6120
Hiroshi TateishiMedicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto 862-0973, Japan.ORCID 0000-0003-1225-0720
Masami OtsukaDepartment of Drug Discovery, Science Farm Ltd., Kumamoto 862-0976, Japan.
Mikako FujitaMedicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto 862-0973, Japan.ORCID 0000-0001-6705-4052
Amaç Fatih TuYuNDepartment of Chemistry, Faculty of Science, Istanbul University, Fatih, Istanbul 34126, Turkey.ORCID 0000-0001-5698-1109
Kumamoto University · JPFatih University · TRAnadolu University · TRGebze Technical University · TRIstanbul University-Cerrahpaşa · TRIzmir Kâtip Çelebi University · TRKoç University · TR

Funding

the Scientific Research Projects Coordination Unit of Istanbul University Project ID: 38594TUBITAK 2236 CoCirculation2 grant number 121C063
6 · The paper itself

Abstract

Colorectal cancer (CRC), breast cancer, and chronic myeloid leukemia (CML) are life-threatening malignancies worldwide. Although potent therapeutic and screening strategies have been developed so far, these cancer types are still major public health problems. Therefore, the exploration of more potent and selective new agents is urgently required for the treatment of these cancers. Quinones represent one of the most important structures in anticancer drug discovery. We have previously identified a series of quinone-based compounds (

Indexed as

Antineoplastic AgentsNeoplasmsBenzoquinonesCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular Docking SimulationMolecular StructureQuinonesStructure-Activity RelationshipAntineoplastic AgentsBenzoquinonesquinoneQuinonesapoptosisbreast cancerCMLCRCDNA binding potentialdrug-likenessmolecular dockingquinone

Identifiers

PMID36615273
PMCPMC9822417
OpenAlexW4313590933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.